PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL

ABSTRACT:

SUBMITTER: Sharp A 

PROVIDER: S-EPMC9431483 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature